Symbicort SMART (Symbicort Maintenance And Reliever Therapy) - Tabular View

Tracking Information

First Received Date ^ICMJE

August 29, 2007

Last Updated Date

July 10, 2009

Start Date ^ICMJE

July 2007

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00523679 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Symbicort SMART (Symbicort Maintenance And Reliever Therapy)

Official Title ^ICMJE

SMART (Symbicort Maintenance And Reliever Therapy): Reassure Program for Patients Using Symbicort Turbuhaler as Maintenance and Reliever Therapy in Korean Clinical Practice

Brief Summary

The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.

Detailed Description

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Case-Only, Prospective

Condition ^ICMJE

Asthma

Intervention ^ICMJE

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Estimated Enrollment ^ICMJE

2000

Completion Date

July 2008

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this program.

Exclusion Criteria:

Since this programme intends to describe Symbicort use in routine clinical practice when prescribed as Symbicort maintenance and reliever therapy, there are no programme specific exclusion criteria, other than: involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)

Gender

Both

Ages

12 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Korea, Republic of

Administrative Information

NCT ID ^ICMJE

NCT00523679

Responsible Party

Study ID Numbers ^ICMJE

NIS-RKR-SYM-2007/1

Study Sponsor ^ICMJE

AstraZeneca

Collaborators ^ICMJE

Investigators ^ICMJE

Study Director:

Joon-Woo Bahn

AstraZeneca Korea

Information Provided By

AstraZeneca

Verification Date

July 2009

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP